You are here

CREST Weekly: How to Manage Rectal GIST

CREST Weekly: How to Manage Rectal GIST | ASCRS

In this CREST module, "How to Manage Rectal GIST" get a review of GIST tumors, 

arise from interstitial cells of Cajal and stain for CD117 antigen, a marker for KIT tyrosine kinase oncoprotein. Imatinib targets this oncoprotein and is the drug of choice for the treatment of GIST. Rectal GIST represents 5% of all GIST and the first line of treatment is surgical excision. Frequently these tumors also require neoadjuvant therapy in order to obtain negative margins and downsize the tumor, or postoperatively in the adjuvant setting.

Upon completion of this module, participants should be able to:

  • Describe the main features of GIST tumors.
  • Evaluate surgical indications for rectal GIST.
  • Describe types of surgery for rectal GIST based on location and size.
  • Evaluate the role of neoadjuvant vs. adjuvant therapy in the management of rectal GIST.

As a Core Subject, it is eligible for 1 AMA PRA Category 1 Credits™.

The ASCRS Online Learning Center provides access to both CREST and CARSEP.  Using your ASCRS website login, you will have access to up-to-date information on colorectal diseases.